Khat, Dorrin Zarrin
Husain, Mansoor
Article History
First Online: 9 June 2018
Compliance with Ethical Standards
:
: Dorrin Zarrin Khat declares no conflict of interest.Mansoor Husain reports grants from Merck & Co, NovoNordisk, and Astra Zeneca. He reports personal fees from Merck, Novo Nordisk, Astra Zeneca, Boehinger Ingelheim, and Jannsen (Johnson & Johnson). In addition, Dr. Husain has a patent pending for Methods for inhibiting platelet aggregation using GLP-1 receptor agonists (Applied, Patents #: US61/721,819, United States), and a patent pending for Peptides and methods for preventing ischemic tissue injury (Applied, Patents #: US61/719,075, United States).
: This article does not contain any studies with human or animal subjects performed by any of the authors.